Showing results (81-90 of 110) with videos related to
Sort By:
Pageof 11
Annals of Neurology|September 18, 2001
Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsyS Nishino, B Ripley, S Overeem, et al.Bioorganic & Medicinal Chemistry Letters|May 16, 2009
Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonistsAlexandre V Ivachtchenko, Eugene B Frolov, Oleg D Mitkin, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|October 7, 2014
Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruptionK B Gordon, A B Gottlieb, R G Langely, et al.Journal of the American Academy of Dermatology|March 19, 2011
Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label studyBruce E Strober, Yves Poulin, Francisco A Kerdel, et al.The British Journal of Dermatology|August 18, 2012
Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trialB E Strober, J M Sobell, K C Duffin, et al.Journal of Medicinal Chemistry|May 27, 2005
Synthesis and structure-activity relationship of 4-substituted 2-(2-acetyloxyethyl)-8-(morpholine-4-sulfonyl)pyrrolo[3,4-c]quinoline-1,3-diones as potent caspase-3 inhibitorsDmitri V Kravchenko, Yulia A Kuzovkova, Volodymyr M Kysil, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|July 16, 2019
Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trialB E Elewski, C S Baker, J J Crowley, et al.American Journal of Clinical Dermatology|November 30, 2010
Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trialAlexa B Kimball, Arielle G Bensimon, Annie Guerin, et al.The British Journal of Dermatology|July 22, 2014
Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatmentA B Kimball, G B E Jemec, M Yang, et al.Journal of the American Academy of Dermatology|September 18, 2017
Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativaIltefat H Hamzavi, Murali Sundaram, Cynthia Nicholson, et al.Pageof 11